A Comparison of Ocular Complications after 0.7 mg Dexamethasone Implant versus 2 mg of Intravitreal Triamcinolone in Vitrectomized Eyes

被引：0
|
作者：
Wakabayashi, Taku
Liu, Catherine K.
Anderson, Hannah E.
Mahmoudzadeh, Raziyeh
Nguyen, Michael K.
Salabati, Mirataollah
Chiang, Allen
Hsu, Jason
Garg, Sunir J.
Spirn, Marc J.
机构：
来源：
OPHTHALMOLOGY | 2023年 / 130卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：660 / 661
页数：2
相关论文
共 50 条
  • [31] Secondary Glaucoma After Intravitreal Dexamethasone 0.7 mg Implant in Patients with Retinal Vein Occlusion: A One-Year Follow-Up
    Meyer, Linda M.
    Schoenfeld, Carl-Ludwig
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2013, 29 (06) : 560 - 565
  • [32] OZURDEX® (Dexamethasone Intravitreal Implant) 0.7 mg for Use in Noninfectious Posterior Segment Uveitis: A Case-Based Discussion
    Cunningham, Emmett T., Jr.
    Goldstein, Debra A.
    Vitale, Albert T.
    Merrill, Pauline T.
    Dacey, Mark S.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2017, 37 : 1 - 15
  • [33] The efficacy and safety outcomes of the 0.19 mg fluocinolone acetonide implant after prior treatment with the 0.7 mg dexamethasone implant in patients with diabetic macular edema
    Singh, P.
    Chedid, A.
    Deuchler, S. K.
    Kohnen, T.
    Mueller, M.
    Koch, F. H.
    INTERNATIONAL MEDICAL CASE REPORTS JOURNAL, 2018, 11 : 265 - 269
  • [34] Resolution of Pseudophakic Cystoid Macular Edema: 2 mg Intravitreal Triamcinolone Acetonide versus 40 mg Posterior Sub-Tenon Triamcinolone Acetonide
    Kuley, Brandon
    Storey, Philip P.
    Wibbelsman, Turner D.
    Pancholy, Maitri
    Zhang, Qiang
    Sharpe, James
    Bello, Nicholas
    Obeid, Anthony
    Regillo, Carl
    Kaiser, Richard S.
    Chiang, Allen
    Fineman, Mitchell S.
    Vander, James F.
    Gupta, Omesh P.
    Spirn, Marc J.
    Dunn, James P.
    Mehta, Sonia
    Park, Carl H.
    Maguire, Joseph I.
    Garg, Sunir
    CURRENT EYE RESEARCH, 2021, 46 (06) : 824 - 830
  • [35] Rhegmatogenous Retinal Detachment with a High Risk of Proliferative Vitreoretinopathy Treated with Episcleral Surgery and an Intravitreal Dexamethasone 0.7-mg Implant
    Reibaldi, Michele
    Russo, Andrea
    Longo, Antonio
    Bonfiglio, Vincenza
    Uva, Maurizio G.
    Gagliano, Caterina
    Toro, Mario D.
    Avitabile, Teresio
    CASE REPORTS IN OPHTHALMOLOGY, 2013, 4 (01): : 79 - 83
  • [36] Retrospective, Observational Study in Patients Receiving a Dexamethasone Intravitreal Implant 0.7 mg for Macular Oedema Secondary to Retinal Vein Occlusion
    Augustin, Albert J.
    Holz, Frank G.
    Haritoglou, Christos
    Mayer, Wolfgang J.
    Bopp, Silvia
    Scheuerle, Alexander F.
    Maier, Matthias
    Sekundo, Walter
    Sandner, Dirk
    Shirlaw, Andrew
    Hattenbach, Lars-Olof
    OPHTHALMOLOGICA, 2015, 233 (01) : 18 - 26
  • [37] A New Approach for Diabetic Macular Edema Treatment: Review of Clinical Practice Results with 0.19 mg Fluocinolone Acetonide Intravitreal Implant Including Vitrectomized Eyes
    Raquel Estebainha
    Raquel Goldhardt
    Manuel Falcão
    Current Ophthalmology Reports, 2020, 8 : 1 - 10
  • [38] A New Approach for Diabetic Macular Edema Treatment: Review of Clinical Practice Results with 0.19 mg Fluocinolone Acetonide Intravitreal Implant Including Vitrectomized Eyes
    Estebainha, Raquel
    Goldhardt, Raquel
    Falcao, Manuel
    CURRENT OPHTHALMOLOGY REPORTS, 2020, 8 (01) : 1 - 10
  • [39] Evaluation of the efficacy of the intravitreal 0.7 mg dexamethasone implant in patients with Diabetic Macular Oedema (DMO) in a Tertiary Referral Center in United Kingdom
    Tasiopoulou, Anastasia
    Kern, Christoph
    Fu, Dun Jack
    Balaskas, Konstantinos
    Keane, Pearse Andrew
    Sim, Dawn A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [40] Comparison of 1mg versus 2mg Dexamethasone Suppression Test in Patients with Obesity
    Urwyler, Sandrine Andrea
    Cupa, Nina
    Christ-Crain, Mirjam
    HORMONE AND METABOLIC RESEARCH, 2017, 49 (11) : 854 - 859
12345